drugset / Trial / NCT00232375

Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes

NCT00232375

Completed 42 enrolled Tokyo Study Group
RandomizedParallel-groupOpen-labelPrevention

Summary

We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a preferable outcome to reverse or preserve beta cell function in the patients with diabetes that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent autoimmune diabetes in adult (LADA).

Timeline

Start
1996-01
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic

Indications

No indication recorded.